查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1618849

患者來源的異質骨移植/PDX 模型市場：按類型、腫瘤類型、應用、最終用戶 - 2025-2030 年全球預測

Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，患者來源的異質骨移植/PDX模型市場價值為3.2636億美元，預計到2024年將達到3.6524億美元，複合年成長率為12.27%，預計到2030年將達到3.2636億美元。億美元。

患者來源的異種移植（PDX）模型是癌症研究的重要工具，是體外研究和臨床應用之間的重要橋樑。在這個模型中，人類腫瘤組織被移植到免疫力缺乏小鼠體內，以維持患者腫瘤的遺傳異質性。這種保真度使得 PDX 模型在加速臨床前測試和個人化醫療舉措方面具有不可估量的價值。對 PDX 模型的需求在於它們能夠提供更準確的治療效果預測，從而幫助藥物開發並克服傳統細胞株模型的限制。 PDX模型主要應用於腫瘤學，支持抗癌藥物篩檢和生技藥品開發。主要最終用戶包括研究機構、製藥公司和委外研發機構(CRO)。

主要市場統計
基準年[2023] 3.2636億美元
預計年份 [2024] 3.6524億美元
預測年份 [2030] 73407萬美元
複合年成長率（%） 12.27%

PDX 模型市場是由癌症發病率上升、癌症藥物研發管線強勁以及對精準醫療的日益重視所推動的。基因編輯和定序的技術進步也顯著促進了市場成長。新的發展機會包括整合人工智慧進行資料分析以及開發3D PDX模型以增強腫瘤微環境的模擬。公司可以透過投資這些領域來利用這些機會，以提高其模型的準確性和可預測性。然而，模型開拓的高成本、動物使用的道德問題以及小型生物技術公司的准入機會有限等挑戰可能會阻礙市場成長。

為了促進創新，我們需要最佳化開發流程以降低成本，增加模型多樣性以涵蓋罕見癌症類型，並將 PDX 結果與患者結果相關聯。我們還可以透過加強學術機構和產業之間的合作來促進創新。 PDX 模型市場高度活躍，其特點是持續的技術進步和旨在擴大服務組合和地理覆蓋範圍的策略聯盟和收購驅動的競爭格局。

市場動態：針對快速發展的患者來源異質骨移植/PDX 模型市場揭示的關鍵市場見解

供需的動態交互作用正在改變患者來源的異質骨移植/PDX 模型市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 個人化醫療需求不斷成長
    • 腫瘤學和臨床前開發
    • 為申請人的臨床前計劃和文件提供政府計劃資助和服務
  • 市場限制因素
    • 個人化 PDX 模型高成本
  • 市場機會
    • 對人性化 PDX 模型的需求不斷成長
    • 藥物研發的成長
  • 市場挑戰
    • 在癌症研究中道德使用動物的嚴格準則

波特五力：駕馭病患來源異質骨移植/PDX 模型市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解病患來源的異質骨移植/PDX 模型市場的外部影響

外部宏觀環境因素在塑造患者異質骨移植/PDX 模型市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解病患來源的異質骨移植/PDX 模型市場的競爭格局

對患者衍生異質骨移植/PDX 模型市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣病患來源異質骨移植/PDX模型市場供應商的績效評估

FPNV定位矩陣是評估病患性異質骨移植/PDX模型市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了患者來源的異質骨移植/PDX 模型市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對患者來源的異質骨移植/PDX 模型市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 個人化醫療需求不斷成長
      • 腫瘤學和臨床前開發
      • 為申請人準備臨床前計劃和文件提供政府計劃資助和服務
    • 抑制因素
      • 個性化PDX模型高成本
    • 機會
      • 對人性化 PDX 模型的需求不斷成長
      • 藥物研發的成長
    • 任務
      • 在癌症研究中道德使用動物的嚴格準則
  • 市場區隔分析
    • 類型：透過在腫瘤學中廣泛使用小鼠模型來開發新治療方法
    • 腫瘤類型：聚焦婦科腫瘤模型，研究婦科癌症
    • 應用：擴大病患來源的異種移植（PDX）模型在基礎癌症研究中的採用
    • 最終使用者：擴大學術研究機構中病患來源的異種移植的範圍
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章患者來源的異質骨移植移植/PDX 模型市場：按類型

  • 小鼠模型
  • 大鼠模型

第 7 章按腫瘤類型分類的病人來源異質骨移植/PDX 模型市場

  • 胃腸道腫瘤模型
  • 婦科腫瘤模型
  • 血液腫瘤模型
  • 呼吸道腫瘤模型
  • 泌尿系統腫瘤模型

第8章患者來源的異質骨移植移植/PDX 模型市場：依應用分類

  • 基礎癌症研究
  • 生物標記分析
  • 臨床前藥物開發

第 9 章 病患來源的異質骨移植/PDX 模型市場：依最終使用者分類

  • 學術/研究機構
  • 合約調查機構
  • 製藥和生物技術公司

第10章 美洲病患來源異質骨移植/PDX模型市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區病患源性異質骨移植/PDX模型市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲病患來源的異質骨移植/PDX模型市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Invivo Biosystems 和 Bioreperia 合作利用先進的 PDX 模型為癌症藥物測試提供動力
    • Kiyatec 和 Xenostart 正式宣布達成合作協議，將使用 Kiyatec 的 3D 球體篩檢平台 Kiya-Predict 提供相關的體外療效資料並幫助降低藥物開發成本。
    • Soteria 和 Certis 合作使用 AI 平台和小鼠異種移植物生成藥物反應預測
  • 戰略分析和建議

公司名單

  • Abnova Corporation
  • Altogen Labs
  • Aragen Life Sciences Pvt. Ltd.
  • BioDuro LLC
  • BioReperia AB
  • Champions Oncology, Inc.
  • Creative Biolabs
  • Crown Bioscience by JSR Corporation
  • EPO Berlin-Buch GmbH
  • GemPhamatech LLC
  • Hera BioLabs Inc.
  • Inotiv, Inc. by Bioanalytical Systems, Inc.
  • InSphero AG
  • LIDE Shanghai Biotech, Ltd.
  • Oncodesign Services
  • Pharmatest Services LLC by ValiRx Finland Oy
  • TheraIndx Lifesciences Pvt. Ltd.
  • Urosphere SAS
  • WuXi AppTec Co., Ltd.
  • XENTECH TECHNOLOGIES PRIVATE LIMITED
Product Code: MRR-FF1601152744

The Patient-Derived Xenograft/PDX Model Market was valued at USD 326.36 million in 2023, expected to reach USD 365.24 million in 2024, and is projected to grow at a CAGR of 12.27%, to USD 734.07 million by 2030.

Patient-Derived Xenograft (PDX) models are indispensable tools in cancer research, representing a crucial bridge between in vitro studies and clinical applications. These models involve transplanting human tumor tissues into immunocompromised mice, thus maintaining the genetic heterogeneity of the patient's tumor. This fidelity makes PDX models invaluable for preclinical testing and accelerating personalized medicine initiatives. The necessity of PDX models lies in their ability to provide more accurate predictions of treatment efficacy, thereby aiding drug development and overcoming the limitations of traditional cell line models. They are primarily applied in oncology, supporting the screening of anti-cancer drugs and the development of biologics. The primary end-users include research institutions, pharmaceutical companies, and contract research organizations (CROs).

KEY MARKET STATISTICS
Base Year [2023] USD 326.36 million
Estimated Year [2024] USD 365.24 million
Forecast Year [2030] USD 734.07 million
CAGR (%) 12.27%

The market for PDX models is driven by the increasing prevalence of cancer, a robust pipeline of oncology drugs, and the growing emphasis on precision medicine. Technological advancements in gene editing and sequencing are also significantly propelling market growth. Emerging opportunities include the integration of artificial intelligence for data analysis and the development of 3D PDX models, which offer enhanced tumor microenvironment simulation. Companies can capitalize on these opportunities by investing in these areas to enhance model accuracy and predictability. However, challenges such as high costs of model development, ethical concerns regarding animal use, and limited accessibility for small biotechs may impede market growth.

To spur innovation, research should focus on optimizing the development process to reduce costs, increasing model diversity to cover rare cancer types, and advancing the co-clinical trial design to better correlate PDX findings with patient outcomes. Increasing collaborations between academic institutions and industry can also expedite innovation. The PDX model market is highly dynamic, characterized by continuous technological advances and a competitive landscape marked by strategic partnerships and acquisitions aimed at expanding service portfolios and geographical reach.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Patient-Derived Xenograft/PDX Model Market

The Patient-Derived Xenograft/PDX Model Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing demand for personalized medicine
    • Oncology and preclinical development
    • Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
  • Market Restraints
    • High cost of personalized PDX model
  • Market Opportunities
    • Rising demand for humanized PDX Model
    • Growth in pharma R&D
  • Market Challenges
    • Stringent guidelines regarding the ethical use of animals in cancer research

Porter's Five Forces: A Strategic Tool for Navigating the Patient-Derived Xenograft/PDX Model Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Patient-Derived Xenograft/PDX Model Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Patient-Derived Xenograft/PDX Model Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Patient-Derived Xenograft/PDX Model Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Patient-Derived Xenograft/PDX Model Market

A detailed market share analysis in the Patient-Derived Xenograft/PDX Model Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Patient-Derived Xenograft/PDX Model Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Patient-Derived Xenograft/PDX Model Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Patient-Derived Xenograft/PDX Model Market

A strategic analysis of the Patient-Derived Xenograft/PDX Model Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., BioDuro LLC, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera BioLabs Inc., Inotiv, Inc. by Bioanalytical Systems, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Oncodesign Services, Pharmatest Services LLC by ValiRx Finland Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and XENTECH TECHNOLOGIES PRIVATE LIMITED.

Market Segmentation & Coverage

This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Mice Models and Rat Models.
  • Based on Tumor Type, market is studied across Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models, Respiratory Tumor Models, and Urological Tumor Models.
  • Based on Application, market is studied across Basic Cancer Research, Biomarker Analysis, and Preclinical Drug Development.
  • Based on End-User, market is studied across Academic & Research Institutions, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for personalized medicine
      • 5.1.1.2. Oncology and preclinical development
      • 5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of personalized PDX model
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising demand for humanized PDX Model
      • 5.1.3.2. Growth in pharma R&D
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Extensive use of mouse models in oncology to develop novel therapeutics
    • 5.2.2. Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
    • 5.2.3. Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
    • 5.2.4. End-User: Rising applicability of patient-derived xenografts in academic and research institutes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Patient-Derived Xenograft/PDX Model Market, by Type

  • 6.1. Introduction
  • 6.2. Mice Models
  • 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 7.1. Introduction
  • 7.2. Gastrointestinal Tumor Models
  • 7.3. Gynecological Tumor Models
  • 7.4. Hematological Tumor Models
  • 7.5. Respiratory Tumor Models
  • 7.6. Urological Tumor Models

8. Patient-Derived Xenograft/PDX Model Market, by Application

  • 8.1. Introduction
  • 8.2. Basic Cancer Research
  • 8.3. Biomarker Analysis
  • 8.4. Preclinical Drug Development

9. Patient-Derived Xenograft/PDX Model Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutions
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Patient-Derived Xenograft/PDX Model Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Invivo Biosystems and Bioreperia Partner to Enhance Cancer Drug Testing with Advanced PDX Models
    • 13.3.2. Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec's 3D Spheroid Screening Platform, Kiya-Predict
    • 13.3.3. Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abnova Corporation
  • 2. Altogen Labs
  • 3. Aragen Life Sciences Pvt. Ltd.
  • 4. BioDuro LLC
  • 5. BioReperia AB
  • 6. Champions Oncology, Inc.
  • 7. Creative Biolabs
  • 8. Crown Bioscience by JSR Corporation
  • 9. EPO Berlin-Buch GmbH
  • 10. GemPhamatech LLC
  • 11. Hera BioLabs Inc.
  • 12. Inotiv, Inc. by Bioanalytical Systems, Inc.
  • 13. InSphero AG
  • 14. LIDE Shanghai Biotech, Ltd.
  • 15. Oncodesign Services
  • 16. Pharmatest Services LLC by ValiRx Finland Oy
  • 17. TheraIndx Lifesciences Pvt. Ltd.
  • 18. Urosphere SAS
  • 19. WuXi AppTec Co., Ltd.
  • 20. XENTECH TECHNOLOGIES PRIVATE LIMITED

LIST OF FIGURES

  • FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
  • FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
  • TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023